CompletedEarly Phase 1NCT03665636
Anaplerotic Therapy Using Triheptanoin for Patients With Glycogen Storage Disease Type I
Studying Glycogen storage disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Areeg El-Gharbawy
- Principal Investigator
- Areeg El-Gharbawy, MDDuke University, Department of Pediatrics - Medical Genetics
- Intervention
- Triheptanoin(drug)
- Enrollment
- 4 enrolled
- Eligibility
- 65 years · All sexes
- Timeline
- 2020 – 2021
Study locations (1)
- Duke University Medical Center, Durham, North Carolina, United States
Collaborators
Ultragenyx Pharmaceutical Inc
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03665636 on ClinicalTrials.govOther trials for Glycogen storage disease
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07459582Accuracy of Home Lactate Meter and Accu-chek Glucometer in Patients With Glycogen Storage DiseaseConnecticut Children's Medical Center
- RECRUITINGNANCT06852612Dietary Treatment Strategies and Metabolic Control in Glycogen Storage Disease Type IInsel Gruppe AG, University Hospital Bern
- RECRUITINGNCT06843330Accuracy of Lactate Meter in GSDIaConnecticut Children's Medical Center
- RECRUITINGNCT06396546'Glycogen Storage Diseases (GSDs) in Indian Children- Establishing an Indian GSD (I-GSD) Registry'Institute of Liver and Biliary Sciences, India
- RECRUITINGNCT04454216GSD VI and GSD IX Natural HistoryDuke University